# Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

> **NCT00338585** · PHASE3 · TERMINATED · sponsor: **ARCA Biopharma, Inc.** · enrollment: 300 (—)

## Conditions studied

- Arterial Occlusive Diseases

## Interventions

- **DRUG:** alfimeprase

## Key facts

- **NCT ID:** NCT00338585
- **Lead sponsor:** ARCA Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 300 (—)
- **Why stopped:** Based upon preliminary safety and efficacy results from a similar study.
- **Last updated:** 2008-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338585, "Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00338585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*